- Sweden
- /
- Life Sciences
- /
- OM:BIOT
Director of Biotage Peter von Ehrenheim Buys 2,563% More Shares
Biotage AB (publ) (STO:BIOT) shareholders (or potential shareholders) will be happy to see that the Director, Peter von Ehrenheim, recently bought a whopping kr47m worth of stock, at a price of kr115. That purchase boosted their holding by 2,563%, which makes us wonder if the move was inspired by quietly confident deeply-felt optimism.
Check out our latest analysis for Biotage
The Last 12 Months Of Insider Transactions At Biotage
In fact, the recent purchase by Peter von Ehrenheim was the biggest purchase of Biotage shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of kr120 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. In this case we're pleased to report that the insider purchases were made at close to current prices.
While Biotage insiders bought shares during the last year, they didn't sell. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Biotage is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data suggests Biotage insiders own 0.1% of the company, worth about kr14m. However, it's possible that insiders might have an indirect interest through a more complex structure. I generally like to see higher levels of ownership.
So What Do The Biotage Insider Transactions Indicate?
It's certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. Insiders likely see value in Biotage shares, given these transactions (along with notable insider ownership of the company). While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of Biotage.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Valuation is complex, but we're here to simplify it.
Discover if Biotage might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:BIOT
Biotage
Provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing.
Flawless balance sheet with proven track record.
Market Insights
Weekly Picks

The "Physical AI" Monopoly – A New Industrial Revolution
Czechoslovak Group - is it really so hot?

The Compound Effect: From Acquisition to Integration
Recently Updated Narratives

Very Bullish

A Tale of Two Engines: Coca-Cola HBC (EEE.AT)

This strategic transformation of TTE? Significant re-rating potential
Popular Narratives
Undervalued Key Player in Magnets/Rare Earth

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks
Trending Discussion
When was the last time that Tesla delivered on its promises? Lets go through the list! The last successful would be the Tesla Model 3 which was 2019 with first deliveries 2017. Roadster not shipped. Tesla Cybertruck global roll out failed. They might have a bunch of prototypes (that are being controlled remotely) And you think they'll be able to ship something as complicated as a robot? It's a pure speculation buy.
This article completely disregards (ignores, forgets) how far China is in this field. If Tesla continues on this path, they will be fighting for their lives trying to sell $40000 dollar robots that can do less than a $10000 dollar one from China will do. Fair value of Tesla? It has always been a hype stock with a valuation completely unbased in reality. Your guess is as good as mine, but especially after the carbon credit scheme got canned, it is downwards of $150.
